• Publications
  • Influence
CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.
TLDR
It is suggested that CCL2 represents a potential therapeutic target that can block the cancer-host communication that prompts CSC-mediated disease progression and is associated with poor differentiation in primary breast cancers.
SGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis
TLDR
This study shows that serum- and glucocorticoid-inducible kinase 3 (SGK3), a kinase transcriptionally regulated by ERα in breast cancer, sustains ERα signaling and drives acquired AI resistance, and proposes SGK3 inhibition as a potential effective treatment of acquired AI-resistant breast cancer.
Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
TLDR
The results suggest that the ER genomic pathway in the ER-positive and Herceptin-resistant breast cancer cells may be reactivated, allowing tamoxifen therapy to be effective again, and a combination of tamoxIFen and Sheceptin can be a potential therapeutic strategy for ER- positive and HerCEPTin- resistant human breast cancer.
Molecular Mechanisms of Polybrominated Diphenyl Ethers (BDE-47, BDE-100, and BDE-153) in Human Breast Cancer Cells and Patient-Derived Xenografts.
TLDR
According to the results from in vitro experiments, the PBDE congeners regulate distinct nuclear receptor signaling pathways, and a mixture of the three congeners with ratios detected in human serum was tested in an ER+ PDX model.
Coordinated Regulation of Serum- and Glucocorticoid-inducible Kinase 3 by a C-terminal Hydrophobic Motif and Hsp90-Cdc37 Chaperone Complex*
TLDR
This study reports that SGK3 stability and kinase activation are regulated by the Hsp90-Cdc37 chaperone complex, and provides new insights into regulation of SGK 3 stability and activation and the rationale for application of Hsp 90 inhibitors in treating SGk3-dependent cancers.
Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer
TLDR
Down-regulation of PDCD4 is associated with AI resistance and a poor prognosis in patients with ER-positive breast cancer, and this down-regulation was inversely correlated with activation of HER2 signaling.
SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.
TLDR
It is reported thatSGK3 is an estrogen receptor (ER) transcriptional target and promotes estrogen-mediated cell survival of ER-positive breast cancer cells and provides a new link between the PI3K pathway and ER signaling as well as a new estrogen- mediated cell survival mechanism mediated by SGK3 in Breast cancer cells.
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.
TLDR
This study identifies SGK3 as an AR target and provides a novel androgen-induced cell proliferation mechanism mediated by the AR-SGK3-p70S6K-cyclin D1 pathway in prostate cancer cells.
...
1
2
...